A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease

Tohru Utsunomiya, Masahiro Okamoto, Shigeki Wakiyama, Masaji Hashimoto, Kengo Fukuzawa, Takahiro Ezaki, Shinichi Aishima, Yasuji Yoshikawa, Taizo Hanai, Hiroshi Inoue, Graham F. Barnard, Masaki Mori

研究成果: ジャーナルへの寄稿記事

8 引用 (Scopus)

抄録

Aim: To study a more accurate quantification of hepatic fibrosis which would provide clinically useful information for monitoring the progression of chronic liver disease. Methods: Using a cDNA microarray containing over 22000 clones, we analyzed the gene-expression profiles of non-cancerous liver in 74 patients who underwent hepatic resection. We calculated the ratio of azanstained: total area, and determined the morphologic fibrosis index (MFI), as a mean of 9 section-images. We used the MFI as a reference standard to evaluate our method for assessing liver fibrosis. Results: We identified 39 genes that collectively showed a good correlation (r > 0.50) between gene-expression and the severity of liver fibrosis. Many of the identified genes were involved in immune responses and cell signaling. To quantify the extent of liver fibrosis, we developed a new genetic fibrosis index (GFI) based on gene-expression profiling of 4 clones using a linear support vector regression analysis. This technique, based on a supervised learning analysis, correctly quantified the various degrees of fibrosis in both 74 training samples (r = 0.76, 2.2% vs 2.8%, P < 0.0001) and 12 independent additional test samples (r = 0.75, 9.8% vs 8.6%, P < 0.005). It was far better in assessing liver fibrosis than blood markers such as prothrombin time (r = -0.53), type IV collagen 7s (r = 0.48), hyaluronic acid (r = 0.41), and aspartate aminotransferase to platelets ratio index (APRI) (r = 0.38). Conclusion: Our cDNA microarray-based strategy may help clinicians to precisely and objectively monitor the severity of liver fibrosis.

元の言語英語
ページ(範囲)383-390
ページ数8
ジャーナルWorld Journal of Gastroenterology
13
発行部数3
DOI
出版物ステータス出版済み - 1 21 2007

Fingerprint

Transcriptome
Liver Cirrhosis
Liver Diseases
Fibrosis
Chronic Disease
Liver
Oligonucleotide Array Sequence Analysis
Clone Cells
Collagen Type IV
Prothrombin Time
Gene Expression Profiling
Hyaluronic Acid
Aspartate Aminotransferases
Genes
Blood Platelets
Regression Analysis
Learning
Gene Expression

All Science Journal Classification (ASJC) codes

  • Gastroenterology

これを引用

A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease. / Utsunomiya, Tohru; Okamoto, Masahiro; Wakiyama, Shigeki; Hashimoto, Masaji; Fukuzawa, Kengo; Ezaki, Takahiro; Aishima, Shinichi; Yoshikawa, Yasuji; Hanai, Taizo; Inoue, Hiroshi; Barnard, Graham F.; Mori, Masaki.

:: World Journal of Gastroenterology, 巻 13, 番号 3, 21.01.2007, p. 383-390.

研究成果: ジャーナルへの寄稿記事

Utsunomiya, T, Okamoto, M, Wakiyama, S, Hashimoto, M, Fukuzawa, K, Ezaki, T, Aishima, S, Yoshikawa, Y, Hanai, T, Inoue, H, Barnard, GF & Mori, M 2007, 'A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease', World Journal of Gastroenterology, 巻. 13, 番号 3, pp. 383-390. https://doi.org/10.3748/wjg.v13.i3.383
Utsunomiya, Tohru ; Okamoto, Masahiro ; Wakiyama, Shigeki ; Hashimoto, Masaji ; Fukuzawa, Kengo ; Ezaki, Takahiro ; Aishima, Shinichi ; Yoshikawa, Yasuji ; Hanai, Taizo ; Inoue, Hiroshi ; Barnard, Graham F. ; Mori, Masaki. / A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease. :: World Journal of Gastroenterology. 2007 ; 巻 13, 番号 3. pp. 383-390.
@article{7e89e3596e10403baa712de0e4e5b729,
title = "A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease",
abstract = "Aim: To study a more accurate quantification of hepatic fibrosis which would provide clinically useful information for monitoring the progression of chronic liver disease. Methods: Using a cDNA microarray containing over 22000 clones, we analyzed the gene-expression profiles of non-cancerous liver in 74 patients who underwent hepatic resection. We calculated the ratio of azanstained: total area, and determined the morphologic fibrosis index (MFI), as a mean of 9 section-images. We used the MFI as a reference standard to evaluate our method for assessing liver fibrosis. Results: We identified 39 genes that collectively showed a good correlation (r > 0.50) between gene-expression and the severity of liver fibrosis. Many of the identified genes were involved in immune responses and cell signaling. To quantify the extent of liver fibrosis, we developed a new genetic fibrosis index (GFI) based on gene-expression profiling of 4 clones using a linear support vector regression analysis. This technique, based on a supervised learning analysis, correctly quantified the various degrees of fibrosis in both 74 training samples (r = 0.76, 2.2{\%} vs 2.8{\%}, P < 0.0001) and 12 independent additional test samples (r = 0.75, 9.8{\%} vs 8.6{\%}, P < 0.005). It was far better in assessing liver fibrosis than blood markers such as prothrombin time (r = -0.53), type IV collagen 7s (r = 0.48), hyaluronic acid (r = 0.41), and aspartate aminotransferase to platelets ratio index (APRI) (r = 0.38). Conclusion: Our cDNA microarray-based strategy may help clinicians to precisely and objectively monitor the severity of liver fibrosis.",
author = "Tohru Utsunomiya and Masahiro Okamoto and Shigeki Wakiyama and Masaji Hashimoto and Kengo Fukuzawa and Takahiro Ezaki and Shinichi Aishima and Yasuji Yoshikawa and Taizo Hanai and Hiroshi Inoue and Barnard, {Graham F.} and Masaki Mori",
year = "2007",
month = "1",
day = "21",
doi = "10.3748/wjg.v13.i3.383",
language = "English",
volume = "13",
pages = "383--390",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "3",

}

TY - JOUR

T1 - A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease

AU - Utsunomiya, Tohru

AU - Okamoto, Masahiro

AU - Wakiyama, Shigeki

AU - Hashimoto, Masaji

AU - Fukuzawa, Kengo

AU - Ezaki, Takahiro

AU - Aishima, Shinichi

AU - Yoshikawa, Yasuji

AU - Hanai, Taizo

AU - Inoue, Hiroshi

AU - Barnard, Graham F.

AU - Mori, Masaki

PY - 2007/1/21

Y1 - 2007/1/21

N2 - Aim: To study a more accurate quantification of hepatic fibrosis which would provide clinically useful information for monitoring the progression of chronic liver disease. Methods: Using a cDNA microarray containing over 22000 clones, we analyzed the gene-expression profiles of non-cancerous liver in 74 patients who underwent hepatic resection. We calculated the ratio of azanstained: total area, and determined the morphologic fibrosis index (MFI), as a mean of 9 section-images. We used the MFI as a reference standard to evaluate our method for assessing liver fibrosis. Results: We identified 39 genes that collectively showed a good correlation (r > 0.50) between gene-expression and the severity of liver fibrosis. Many of the identified genes were involved in immune responses and cell signaling. To quantify the extent of liver fibrosis, we developed a new genetic fibrosis index (GFI) based on gene-expression profiling of 4 clones using a linear support vector regression analysis. This technique, based on a supervised learning analysis, correctly quantified the various degrees of fibrosis in both 74 training samples (r = 0.76, 2.2% vs 2.8%, P < 0.0001) and 12 independent additional test samples (r = 0.75, 9.8% vs 8.6%, P < 0.005). It was far better in assessing liver fibrosis than blood markers such as prothrombin time (r = -0.53), type IV collagen 7s (r = 0.48), hyaluronic acid (r = 0.41), and aspartate aminotransferase to platelets ratio index (APRI) (r = 0.38). Conclusion: Our cDNA microarray-based strategy may help clinicians to precisely and objectively monitor the severity of liver fibrosis.

AB - Aim: To study a more accurate quantification of hepatic fibrosis which would provide clinically useful information for monitoring the progression of chronic liver disease. Methods: Using a cDNA microarray containing over 22000 clones, we analyzed the gene-expression profiles of non-cancerous liver in 74 patients who underwent hepatic resection. We calculated the ratio of azanstained: total area, and determined the morphologic fibrosis index (MFI), as a mean of 9 section-images. We used the MFI as a reference standard to evaluate our method for assessing liver fibrosis. Results: We identified 39 genes that collectively showed a good correlation (r > 0.50) between gene-expression and the severity of liver fibrosis. Many of the identified genes were involved in immune responses and cell signaling. To quantify the extent of liver fibrosis, we developed a new genetic fibrosis index (GFI) based on gene-expression profiling of 4 clones using a linear support vector regression analysis. This technique, based on a supervised learning analysis, correctly quantified the various degrees of fibrosis in both 74 training samples (r = 0.76, 2.2% vs 2.8%, P < 0.0001) and 12 independent additional test samples (r = 0.75, 9.8% vs 8.6%, P < 0.005). It was far better in assessing liver fibrosis than blood markers such as prothrombin time (r = -0.53), type IV collagen 7s (r = 0.48), hyaluronic acid (r = 0.41), and aspartate aminotransferase to platelets ratio index (APRI) (r = 0.38). Conclusion: Our cDNA microarray-based strategy may help clinicians to precisely and objectively monitor the severity of liver fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=33846588883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846588883&partnerID=8YFLogxK

U2 - 10.3748/wjg.v13.i3.383

DO - 10.3748/wjg.v13.i3.383

M3 - Article

VL - 13

SP - 383

EP - 390

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 3

ER -